The medication has a long half-life that provides consistent blood levels throughout the week regardless of injection time
Research shows that a notable proportion of weight lost during GLP-1 treatment can come from lean body mass rather than fat alone - depending on the medication, individual factors, and whether resistance training was maintained during treatment
GLP-1 Receptor Agonist Use Is Associated with Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth
After 84 weeks, tirzepatide participants lost an average of 26.6%, while those on the highest dose of retatrutide lost around 24.2% over 48 weeks
Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
Side Effects to Be Aware of When Using Retatrutide The most common side effects are gastrointestinal, including nausea and vomiting
